Hanneke Kievit is a researcher actively contributing to advancements in non-small cell lung cancer (NSCLC) treatment. Her work focuses on integrating liquid biopsy techniques, immune checkpoint inhibitors, and stereotactic radiotherapy to improve patient outcomes. UN Sustainable Development Goals: Health and Well-being (SDG 3) Her research spans molecular diagnostics, tumor immunology, and minimally invasive technologies. Recent studies highlight her role in clinical trials combining immunotherapy with radiation and refining diagnostic approaches for pulmonary nodules. Collaboration trends reveal partnerships with multidisciplinary teams across institutions, emphasizing translational research in oncology and pulmonology.
Benthe Muntinghe is a medical researcher specializing in non-small cell lung cancer (NSCLC) with active contributions to oncology research between 2022-2025. Her work shows strong collaboration with University Medical Center Groningen researchers, particularly in the fields of immunotherapy and diagnostic innovation. Her research focuses on critical areas of lung cancer treatment including CD8+ T cell activation as a predictor of treatment response, combination therapies involving stereotactic radiotherapy with immune checkpoint inhibitors (durvalumab and tremelimumab), and innovative diagnostic approaches using electronic nose technology for non-invasive lung cancer detection. Her work addresses key challenges in NSCLC treatment personalization and response prediction. Analysis of her publication record reveals a strong emphasis on translational research bridging laboratory findings with clinical applications, particularly in identifying biomarkers for treatment response and developing novel combination therapies. Her work spans diagnostic innovation, therapeutic optimization, and clinical trial design in advanced NSCLC. Her research contributes significantly to UN Sustainable Development Goals related to good health and well-being, particularly through advancements in cancer diagnostics and treatment personalization. Muntinghe's collaborative network demonstrates extensive work with clinical oncology teams, focusing on practical applications of immunotherapy and radiotherapy combinations. Her research trajectory indicates growing involvement in multi-center clinical trials and diagnostic validation studies.
Sanjal Desai, MD serves as an Assistant Professor of Medicine within the Division of Hematology, Oncology, and Transplantation at the University of Minnesota Medical School. His clinical and research focus centers on hematologic malignancies with specialization in lymphoma therapeutics. Dr. Desai's research interests span relapsed/refractory Hodgkin lymphoma , stem cell transplantation optimization , novel immunotherapies (particularly PD-1 inhibitors and brentuximab vedotin), and cardio-oncology interfaces. His work emphasizes real-world evidence generation through multi-center collaborations, addressing critical gaps in post-transplant management, treatment sequencing for dual-refractory disease, and cardiovascular risk mitigation in cancer survivors. Analysis of his recent publications reveals a dominant focus on improving outcomes for classic Hodgkin lymphoma through strategic integration of checkpoint inhibitors with autologous stem cell transplantation, maintenance therapies, and novel salvage regimens. His research consistently leverages large multi-institutional datasets to validate therapeutic approaches in complex clinical scenarios. While no specific awards are listed in the provided materials, his prolific publication output in high-impact journals including JACC: CardioOncology indicates significant scholarly recognition. Dr. Desai actively contributes to advancing lymphoma therapeutics through clinical trial design (notably Phase I/II studies of alemtuzumab combinations and pembrolizumab-based regimens) and large-scale observational studies addressing unmet needs in refractory disease management and survivorship care.
Carol Lange, PhD is a Professor of Medicine and Pharmacology at the University of Minnesota with a joint appointment in the Division of Hematology, Oncology, and Transplantation. Her research bridges molecular endocrinology, cancer biology, and pharmacology, focusing on steroid hormone receptor signaling in hormone-driven cancers. Breast Cancer Steroid Hormone Receptors Cancer Stem Cells Signal Transduction Endocrine Resistance Cancer Metabolism Recent studies highlight her work on progesterone receptor isoform-specific regulation of super enhancers in breast cancer stem cell expansion, glucocorticoid receptor interactions with TGFβ signaling in triple-negative breast cancer, and clinical trials targeting endocrine resistance. These investigations align with emerging themes in tumor microenvironment dynamics and hormone receptor crosstalk. Key collaborations include the SMILE Study (Onapristone + Fulvestrant for ER+/HER2- metastatic breast cancer) and the ONAWA (SOLTI-1802) trial evaluating antiprogestin therapy. Her work also explores metabolic reprogramming, PDK4 activation, and epigenetic regulation in therapy-resistant populations.
Calogero Camma' is a Professor at the University of Palermo's School of Medicine and Surgery, specializing in Health Promotion, Maternal and Child Health, Internal Medicine, and Specialist Medicine. He serves as Responsible for Health Area Specialization Schools under the Rector's authority, with office hours at Clinica Medica I, DIBIMIS, Palermo. Research Focus: Hepatology, Gastroenterology, and Internal Medicine, particularly hepatocellular carcinoma, NAFLD, and viral hepatitis complications Recent Publications: Explored immunotherapy outcomes in HCC, AI applications in gastroenterology, and liver disease progression models Contact: calogero.camma@unipa.it
Paul Klenerman is the Sidney Truelove Professor of Gastroenterology at the University of Oxford, affiliated with the Nuffield Department of Medicine and based at the Peter Medawar Building and Translational Gastroenterology Unit, John Radcliffe Hospital. His research focuses on immune responses to infectious diseases such as HIV, hepatitis B, and C, with a particular emphasis on vaccine development and immune mechanisms. His research spans three main areas: CD161++/MAIT cell biology : investigating their role in host defense and immunopathology through patient analysis and in vitro studies. HCV immune defense : collaborating on vaccine trials using adenoviral vectors and exploring host responses to novel therapies. Memory inflation : studying persistent virus-induced T cell populations and their expansion dynamics. Recent publications highlight his work on hybrid immunity against SARS-CoV-2, MAIT cell functions, liver transplantation immunobiome, and celiac disease ecosystems. Collaborations include key researchers from Harvard, UCL, and University Hospital Freiburg. Key labs and teams: Translational Gastroenterology Unit at John Radcliffe Hospital STOP-HVC website research group
Dr. Roza Nurieva is a Professor in the Department of Immunology at MD Anderson Cancer Center, serving as Principal Investigator of the Nurieva Laboratory. Her research focuses on elucidating the molecular basis of T cell mediated immune responses and how abnormal immune regulation leads to immunodeficiency, autoimmunity and cancer. Institution: MD Anderson Cancer Center Department: Immunology Position: Professor and Principal Investigator Dr. Nurieva's research interests center on T follicular helper cells, T cell tolerance mechanisms, and the role of specific proteins like Grail in immune regulation. Her laboratory has made significant contributions to understanding the molecular framework of T cell differentiation and immune regulation. Recent work demonstrated that transplantation of Grail-deficient T cells into a mouse model of lymphoma inhibits tumor growth, suggesting Grail as a potential therapeutic target for improving cancer immune responses. Her research bridges fundamental immunology with translational applications for cancer therapy and autoimmune disease treatment. Analysis of Dr. Nurieva's publication record reveals consistent focus on immune cell regulation with direct clinical relevance. Her work spans molecular mechanisms of T cell differentiation, immune tolerance, and tumor-immune interactions. Key recurring themes include T follicular helper cell biology, the role of ubiquitin ligases in immune regulation, and molecular pathways of T cell dysfunction in cancer. These research streams converge on developing novel immunotherapeutic approaches that could transform cancer treatment. NR4A1 as mediator of T cell dysfunction IL-22 in Kras-mutant lung cancer progression Molecular regulation of T follicular helper cells GRAIL protein in T cell tolerance Through her leadership at MD Anderson Cancer Center, Dr. Nurieva continues to advance cancer immunology research with the goal of developing more effective immunotherapies that harness the immune system to fight cancer while providing insights applicable to autoimmune disorders.
Nancy J. Anderson is a Professor in the School of Medicine , affiliated with both the Dermatology and Basic Sciences departments. Her work spans clinical dermatology, pharmacology, and immunodermatology. Doctor of Medicine, Loma Linda University, 1976 Bachelor of Arts, Andrews University, 1972 Research interests include skin diseases , biologic therapies , psoriasis , and cutaneous oncology . Recent publications focus on patient reviews in dermatology , adverse effects of biologics , and systematic reviews of dermatologic conditions . Her academic contributions emphasize evidence-based practices , allergic reactions , and laser treatments for vascular and pigmented lesions. No scientific awards or student mentorship details were mentioned in the provided data.
Mohammed Milhem, MBBS, is a Clinical Professor in the Department of Internal Medicine at the University of Iowa's Carver College of Medicine. He is a key leader in oncology research and clinical care, serving as the Associate Director of Clinical Research at the Holden Comprehensive Cancer Center and Director of the Melanoma Program. His work spans melanoma, sarcoma, immunotherapy, and experimental therapeutics. Research Interests: Dr. Milhem's research focuses on improving outcomes in melanoma and sarcoma through immunotherapy, particularly anti-PD-1 agents, and understanding factors influencing treatment response such as antibiotic use and immune-related adverse events. He investigates novel combination therapies including radiation with immunotherapy and targeted agents like pazopanib. His work also explores wound morbidity in sarcoma patients undergoing radiotherapy and the role of natural killer cells in uveal melanoma. Publication Trends: His recent publications (2020–2021) are predominantly clinical and translational, appearing in journals like Cancer , Cancers (Basel) , and Melanoma Research . These reflect a strong emphasis on phase II trials, retrospective analyses, and case reports in sarcoma and melanoma, with a focus on immunotherapy efficacy, toxicity, and predictive biomarkers. Leadership & Clinical Roles: Holden Chair of Experimental Therapeutics Associate Director of Clinical Research, Holden Comprehensive Cancer Center Director, Melanoma Program, Holden Comprehensive Cancer Center Education: MBBS, Jordan University, Amman, Jordan Residency, Internal Medicine, University of Illinois at Chicago Fellowship, Hematology/Oncology, University of Illinois at Chicago Fellowship, Bone Marrow Transplant, University of Illinois at Chicago Professional Certifications: American Board of Internal Medicine American Board of Internal Medicine, Hematology American Board of Internal Medicine, Oncology Advising and Grants: While specific students and grants are not mentioned in the text, Dr. Milhem leads major clinical research initiatives and directs therapeutic programs, suggesting active mentorship and grant-funded research. His role as Holden Chair indicates significant research support. Labs and Teams: Dr. Milhem collaborates extensively within the Holden Comprehensive Cancer Center, particularly in melanoma and sarcoma multidisciplinary teams. He is affiliated with research groups focused on immunotherapy, clinical trials, and experimental therapeutics.
Hester Gietema is a researcher and teacher at the Faculty of Health, Medicine and Life Sciences at Maastricht University (UMS), specializing in Radiology within the GROW - Innovative Cancer Diagnostics & Therapy program. Her work focuses on Medical Imaging , particularly Computed Tomography (CT) , PET-CT , and their applications in Oncology and Lung Disease management. Research Themes : CT image quality assessment, metabolic tumor volume as a biomarker, lung nodule screening, and robotic-assisted surgical interventions. Recent publications highlight collaborations in radiation oncology , thymoma removal , and AI-driven imaging analysis . While specific educational details and awards are not mentioned, her research output spans 2016–2025 , demonstrating sustained expertise in diagnostic imaging and cancer therapy.
David K. Cortez is Professor of Biochemistry and Chair of the Department of Biochemistry at Vanderbilt University School of Medicine. He also holds the Richard N. Armstrong Ph.D. Chair for Innovation in Biochemistry and serves as Associate Director for Basic Science Research at the Vanderbilt-Ingram Cancer Center. His research is centered on genome maintenance, DNA damage response, and replication stress mechanisms. Institution: Vanderbilt University School: School of Medicine Department: Department of Biochemistry Leadership: Chair of Biochemistry, Associate Director (Basic Science), VICC Contact: david.cortez@vanderbilt.edu | 615-322-8547 | 613 Light Hall, Nashville, TN Dr. Cortez's research focuses on understanding how cells maintain genome integrity during DNA replication and in response to DNA damage. His work integrates genetics, biochemistry, cell biology, proteomics, and structural biology to dissect mechanisms involving ATR kinase signaling, replication fork remodeling, BRCA-related pathways, abasic site repair, and proteolysis . These processes are crucial for preventing cancer, developmental disorders, and aging. The 15 most recent publications highlight a consistent focus on DNA damage signaling, replication fork dynamics, and repair mechanisms . Key themes include the use of iPOND for proteomic mapping , fork regression and protection , ATR-mediated checkpoint control , and therapeutic targeting of DNA repair pathways in cancer. Subfields span molecular oncology, signal transduction, and structural enzymology. Scientific recognition includes: Richard N. Armstrong Ph.D. Chair for Innovation in Biochemistry Dr. Cortez leads an active research program with ongoing postdoctoral recruitment, indicating strong grant support and mentoring activity. His lab is embedded in multiple interdisciplinary centers, including the Genome Maintenance Program (Vanderbilt-Ingram Cancer Center), Vanderbilt Institute of Chemical Biology, and Center in Molecular Toxicology , reflecting broad collaborative and funding networks. He advises graduate and postdoctoral researchers in molecular cancer biology and DNA repair. Future work continues to explore therapeutic vulnerabilities in DNA repair-deficient cancers. The Cortez Lab maintains a strong presence in both basic and translational research, with ongoing projects aimed at identifying novel repair proteins, characterizing fork protection mechanisms, and developing cancer therapies targeting the DNA damage response. The lab utilizes cutting-edge techniques such as genetic screens, iPOND, structural biology, and preclinical models.
Elham Khatamzas is a Clinical Professor and Senior Physician in the Department of Infectious and Tropical Medicine at Heidelberg University Hospital (UKHD). She holds academic and clinical roles, including Deputy positions, and specializes in infectious diseases, microbiology, and virology. Her career includes roles at Oxford University Hospital NHS Trust, Charité Berlin, and the University of Oxford (PhD 2012). She has led clinical trials (e.g., OVIVA trial on antibiotic efficacy) and contributed to global health initiatives, such as improving fungal care standards in Brazil. Her research focuses on antimicrobial therapy, fungal infections, and post-COVID complications. Notable work includes studies on nivolumab in fusariosis and rezafungin in candidemia, emphasizing translational and clinical research. She advocates for equity in academia and publishes in high-impact journals like the New England Journal of Medicine and European Journal of Cancer.
Daniel Hodson is a Principal Investigator at the Cambridge Stem Cell Institute and a group leader in the Department of Haematology at the University of Cambridge. He holds an Medical Research Council Clinician Scientist Fellowship and a CRUK Senior Cancer Research Fellowship , focusing on the molecular mechanisms of lymphomagenesis , particularly in B cell lymphomas . His work bridges clinical hematology with cutting-edge genomic and post-transcriptional research. Research Interests : Hodson investigates how genetic alterations in post-transcriptional regulation contribute to non-Hodgkin lymphoma development. His lab employs exome sequencing , ribosome profiling , and iCLIP to study mRNA translation and single-cell perturbational transcriptomics in germinal center B cells . This research has implications for targeted therapies in lymphoid malignancies. Scientific Awards & Funding : CRUK Senior Cancer Research Fellowship (2021) Medical Research Council Clinician Scientist Fellowship Kay Kendal Leukaemia Fund Addenbrooke's Charitable Trust The Evelyn Trust Students & Collaborators : Hodson leads a team including Chun (Jade) Gong , Kaiyue Helian , Ross Jackson , Furqaan Ahmed Kaji , Joanna Krupka , and Judith Mateos . His group develops novel cell culture models for lymphoma research. Lab & Facilities : Based at the Jeffrey Cheah Biomedical Centre on the Cambridge Biomedical Campus, Hodson's lab collaborates with the Haematological Malignancy Research Network and utilizes single-cell technologies , genomics , and bioinformatics core facilities.
Satyendra Kumar Singh is a Researcher at the Institute for Global Health within the College of Engineering at Michigan State University. His work focuses on biomedical engineering applications in oncology, radiation biology, and toxicology. He investigates targeted therapies including alpha-particle emitters, novel PET imaging agents, and mechanisms of chemical warfare agent-induced skin toxicity. Singh’s research integrates preclinical models to evaluate therapeutic efficacy and disease mechanisms. Key research areas include: medical imaging probe development, cancer radiotherapy optimization, inflammatory response modulation in toxicological exposures, and parasitic disease pathogenesis. His work spans translational medicine bridging basic science and clinical applications. Recent studies emphasize immune-competent mouse models for evaluating combined radiation/immunotherapy and the role of mast cells in chemical injury pathways. Publications (2020-2025) reveal a strong focus on: 1) Hepatospecific PET agent design (Cu-64 labeled compounds), 2) Bismuth-212 based targeted radiotherapy for solid tumors, 3) Mechanisms of phosgene oxime-induced skin damage, and 4) RAGE signaling pathways in oncogenesis. Current laboratory work involves developing supersaturated oxygen emulsions for corneal injury treatment and exploring the Lysophosphatidic acid-RAGE axis in tumor progression. Awards section: No specific honors listed in provided materials. Grant information not explicitly detailed but implied through publication activity. Labs/Teams: Active in the Institute for Global Health's biomedical engineering research group, collaborating across departments in the College of Engineering and College of Veterinary Medicine (implied through parasitology work).
Sara Mouton is a Postdoc researcher at the University of Groningen, affiliated with both the Faculty of Science and Engineering and the Faculty of Medical Sciences. Her primary appointment is in the Molecular Systems Biology group under the Groningen Biomolecular Sciences and Biotechnology institute. She holds a PhD (Cum Laude, 2023) and MSc (2016) in Biomedical Sciences with a focus on ageing biology. Her research explores the physicochemical basis of cellular ageing, particularly macromolecular crowding and cytoplasmic organization in yeast. She investigates how physical and chemical parameters shift with age, using tools like FRET-based sensors and in vitro reconstitution of cell cycle processes. Recent projects include studying nuclear pore complex dynamics and stress-induced transport defects linked to ALS. Publications highlight her expertise in nuclear transport mechanisms, protein self-organization, and single-cell analysis of ageing biomarkers. Awards include a Cum Laude distinction for her PhD thesis on physicochemical perspectives of ageing. She collaborates with Prof. Liesbeth Veenhoff and Dr. Julia Kamenz, advancing studies on crowding regulators and cell cycle reconstitution. Her work bridges biophysics, cell biology, and ageing research, with implications for understanding cellular organization and disease mechanisms.
